Back to Search
Start Over
A nomogram for predicting overall survival in patients with resected non-small cell lung cancer treated with chemotherapy.
- Source :
-
Translational lung cancer research [Transl Lung Cancer Res] 2021 Apr; Vol. 10 (4), pp. 1690-1699. - Publication Year :
- 2021
-
Abstract
- Background: Chemotherapy is a common treatment for patients with resected non-small cell lung cancer (NSCLC). However, there are few models for predicting the survival outcomes of these patients. Here, we developed a clinical nomogram for predicting overall survival (OS) in this cohort.<br />Methods: A total of 16,661 patients with resected NSCLC treated with chemotherapy were extracted from the Surveillance, Epidemiology, and End Results (SEER) database. We identified prognostic factors and integrated them into a nomogram. The model was subjected to bootstrap internal validation using the SEER database and external validation using a database in China and the National Cancer Database (NCDB). The model's predictive accuracy and discriminative ability were tested by calibration and concordance index (C-index).<br />Results: Age, sex, number of dissected lymph nodes, extent of surgery, N stage, T stage, and grade were independent factors for OS and were integrated into the model. The calibration curves for probability of 1-, 3-, and 5-year OS showed excellent agreement between the predicted and actual survivals. The C-index of the nomogram was higher than that of the Tumor-Node-Metastasis staging system for predicting OS (training cohort, 0.62 vs. 0.58; China cohort, 0.68 vs. 0.63; NCDB cohort, 0.59 vs. 0.57).<br />Conclusions: We developed a nomogram that can present individual prediction of OS for patients with resected NSCLC who are undergoing chemotherapy. This practical prognostic tool may help clinicians in treatment planning.<br />Competing Interests: Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at http://dx.doi.org/10.21037/tlcr-20-1220). WL serves as an unpaid associate editor-in-chief from Apr 2018 to Apr 2021. The other authors have no conflicts of interest to declare.<br /> (2021 Translational Lung Cancer Research. All rights reserved.)
Details
- Language :
- English
- ISSN :
- 2218-6751
- Volume :
- 10
- Issue :
- 4
- Database :
- MEDLINE
- Journal :
- Translational lung cancer research
- Publication Type :
- Academic Journal
- Accession number :
- 34012785
- Full Text :
- https://doi.org/10.21037/tlcr-20-1220